{"id":499,"date":"2026-09-06T21:49:17","date_gmt":"2026-09-06T21:49:17","guid":{"rendered":"https:\/\/premiumpeptide.shop\/research\/compounds\/semax\/"},"modified":"2026-09-06T21:59:44","modified_gmt":"2026-09-06T21:59:44","slug":"semax","status":"publish","type":"page","link":"https:\/\/premiumpeptide.shop\/en\/research\/compounds\/semax\/","title":{"rendered":"Semax"},"content":{"rendered":"

Semax is a short peptide with a structure derived directly from a natural hormone fragment. The brevity of the sequence makes the analysis comparatively simple, but places its own demands on the separation.<\/p>\n

What is Semax?<\/h2>\n

Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. The first four amino acids correspond to fragment 4 to 7 of adrenocorticotropic hormone, supplemented by the C-terminal tripeptide Pro-Gly-Pro, which increases stability against peptidases. The molecular mass is approximately 814 Da.<\/p>\n

In addition to the basic form, an N-acetylated variant is described in the literature. Acetylation increases the mass by approximately 42 Da and is unambiguously recognisable by mass spectrometry. A product designation without an addition leaves the variant open.<\/p>\n

Research context<\/h2>\n

Semax is described in the neuroscience research literature, predominantly in publications from the Russian-speaking world. In the European Union there is no marketing authorisation as a medicinal product. For laboratory contexts it is relevant that the available literature concerns different preparations and variants and that assignments are not possible without analytical characterisation.<\/p>\n

Analytical identification<\/h2>\n